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Cyclophilins and nucleoporins are 
required for infection mediated 
by capsids from circulating HIV-2 
primary isolates
João I. Mamede1,†, Florence Damond2, Ariel de Bernardo1, Sophie Matheron2, 
Diane Descamps2, Jean-Luc Battini1, Marc Sitbon1 & Valérie Courgnaud1
HIV-2 groups have emerged from sooty mangabey SIV and entered the human population in Africa on 
several separate occasions. Compared to world pandemic HIV-1 that arose from the chimpanzee SIVcpz 
virus, the SIVsm-derived HIV-2, largely confined to West Africa, is less replicative, less transmissible 
and less pathogenic. Here, we evaluated the interactions between host cellular factors, which control 
HIV-1 infection and target the capsid, and HIV-2 capsids obtained from primary isolates from patients 
with different disease progression status. We showed that, like HIV-1, all HIV-2 CA we tested exhibited 
a dependence on cyclophilin A. However, we observed no correlation between HIV-2 viremia and 
susceptibility to hu-TRIM5alpha or dependence to CypA. Finally, we found that all CA from HIV-2 
primary isolates exploit Nup358 and Nup153 for nucleus transposition. Altogether, these findings 
indicate that the ability to use the two latter nucleoporins is essential to infection of human cells for 
both HIV-1 and HIV-2. This dependence provides another molecular target that could be used for 
antiviral strategies against both HIV-1 and 2, based on both nucleoporins.
Cross-species transmission of SIV from sooty mangabeys to humans in West Africa gave rise to at least nine 
HIV-2 groups. HIV-2 remained largely restricted to West Africa1 in contrast to the HIV-1 group M that is respon-
sible for the worldwide AIDS pandemic. HIV-1 group M appeared during a zoonosis from chimpanzee. Among 
the nine known HIV-2 groups, only groups A and B have spread throughout West Africa1–3. Globally this sug-
gests a weaker adaptability of HIV-2 in humans. Indeed, in several West African countries, HIV-2 prevalence 
has been declining while HIV-1 infection has increased4,5. Despite the fact that HIV-1 and HIV-2 have similar 
routes of transmissions, cellular targets, or clinical consequences, the characteristics of disease progression in 
infected patients differ drastically in many ways. The natural course of HIV infection is usually described in three 
stages (acute, latent and AIDS). However, the incidence of immunodeficiency and its progression are significantly 
reduced in HIV-2 patients when compared to patients with HIV-1. HIV-2 transmission is also less efficient6,7 and 
has a lower viral load and a slower decline in CD4+ T-cell counts observed during asymptomatic infection8–11. 
Over 80% (86–95%) of HIV-2 patients can be considered as long-term non progressors (LTNP), while at most 
15% (5–15%) LTNPs are observed in most HIV-1 cohort studies8,11–13. The contributing factors to these differ-
ences remain largely unknown but comparative studies between HIV-1 and HIV-2 infections have led to several 
hypotheses. Thus, it has been proposed that lower rates of T-cell activation in HIV-2 infected patients14–16, better 
immune control11,17,18, lower mutation rates, and replication capacity of HIV-28,19,20 could account for these differ-
ences. Yet, in at least 10% of HIV-2 infected patients the profile of infection is similar to that observed with HIV-1. 
Therefore, we reasoned that the comparison of isolates from HIV-2 rapid progressors (RP; high viral load, CDC 
stage C) versus HIV-2 LTNP (undetectable viral load, CDC stage A) might be more informative than the overall 
comparison of the two types of viruses.
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After entering in a new host cell, retroviruses must hijack cellular host proteins to complete many aspects 
of their viral replication cycle while counteracting cellular restriction factors. These are components of the 
innate immune response21 such as the apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 
3G (APOBEC3G)22 BST-2/CD317/tetherin23,24, TRIM5alpha proteins25, the SAM domain and HD 
domain-containing protein 1 (SAMHD1)26,27 or the myxovirus resistance 2 (MX2)28,29. HIV-2 has been transmit-
ted to humans from sooty mangabeys, a lower monkey species compared to chimpanzees. Therefore it has been 
evoked that HIV-2 may be more susceptible to innate human restriction factors than HIV-1. A possible correla-
tion between variations in the sequences of HIV-2 strains and the capacity to replicate in humans, associated with 
clinical progression to AIDS has been previously envisaged. For example, a yet unidentified factor, called Lv2, 
may restrict certain HIV-2 strains after virus entry, but not HIV-130,31, and more recently, the RNA-associated 
early-stage anti-viral factor (REAF) has been shown to inhibit HIV-1 and HIV-2 to a higher level32.
After retroviral entry, the viral capsid (CA) which plays an important role during the early steps of the viral 
cycle, i.e. uncoating, reverse transcription, nuclear import and integration33, becomes an important target to host 
cellular factors, and influences innate responses such as DNA sensing mediated by cGAS/PQBP1 through the 
STING pathway in cells of myeloid origin34,35.
One of the restriction factors recognizing the incoming capsid is the primate TRIM5alpha factor, a cellular E3 
ubiquitin ligase that restricts infection and promotes innate immune signaling in response to retroviral infection36–38. 
TRIM5alpha blocks viral infection before reverse transcription and is species-specific25. Several single nucleotide 
polymorphisms (SNPs) in human TRIM5alpha have been found to modulate HIV-1 infection, notably in regard 
of the time taken to disease progression39 and its correlation with different restriction potentials40–42. However, 
association between human TRIM5alpha variation and HIV-2 has not yet been described. Overall, HIV-2 is more 
sensitive to restriction by TRIM5alpha than HIV-143–46 and variations in sensitivity have been linked to specific 
proline residues within the HIV-2 capsids47,48. However, there is no clear correlation between ex vivo susceptibility 
to TRIM5alpha and viral loads in patients45.
In addition to differences in sensitivity of HIV-2 to the already identified innate cellular factors when com-
pared to HIV-1, is that HIV-2 could exploit the recruitment of alternative host factors for optimal infection. 
Interestingly, cyclophilin A (CypA) that is encoded by the peptidyl prolyl isomerase A gene (PPIA), is an essential 
cofactor of the early steps of HIV-1 infection in human cells49–51. While CypA interacts specifically with HIV-1 
CA52,53, its interaction with HIV-2 CA is not clear54–56.
In a previous study, we have shown that both HIV-1 and HIV-2 prototypes exploit the same pathway to enter 
the nucleus, i.e. a dependence on the CypA, Nup358 and Nup153 factors57, which may reflect an adaptation to 
human cells for high replication. However, little is known on the overall susceptibility of different HIV-2 pri-
mary isolates to host factors and progression to disease. Since CA determinants play an essential role in the early 
stages of viral replication, the aim of our study was to evaluate the interactions of HIV-2 p26/CA determinants, 
with CA-interacting cellular proteins, including cytoplasmic TRIM5 proteins, CypA and nucleopore-associated 
Nup358 and Nup153. The CA variants were derived from HIV-2 primary isolates obtained from either asympto-
matic or symptomatic patients that were included in the French ANRS Cohort CO5.
Results
In order to investigate the susceptibility to different intracellular host factors of CA that are present in primary 
isolates from viremic or aviremic HIV-2 patients, we amplified and sequenced the matrix-capsid (MACA) regions 
from DNA extracted PBMCs of 18 HIV-2 infected participants included in the French ANRS Cohort CO5 (10 
symptomatic and 8 asymptomatic). All of the HIV-2 sequences that were obtained belonged to the epidemic 
groups A or B. We then chose to further assess the sequences that differed in CA at specific positions (proline 
residues at positions 119, 159 and 178) that have previously been described as differentiating between low and 
high viral load individuals47, as well as to play a role in TRIM5alpha restriction. Sequences found in RP (high viral 
load, severely symptomatic) or LTNP (undetectable viral load, asymptomatic) patients were closely related to each 
other, including in the CypA-binding loop (Fig. S1). Although the HIV-2ROD prototype has a “PPP” motif, this 
motif was not found in our patients. Nevertheless, all of the RP had a P at position 178. After analysis of multiple 
sequences from primary isolates, we noted that “APP” was the most frequent motif. We therefore selected the CA 
from two patients with “APP” to test whether any other variations in CA sequence could account for phenotypical 
differences. The virological and clinical characteristics of these HIV-2 patients are summarized in Table 1.
In order to functionally address these points, we introduced different versions of HIV-2 MACA within a 
gag-pol SIVmac expression vector using a previously validated strategy57. The resulting chimeric were used to 
produce single-round infection viruses. Upon transfection of HEK-293T cells, we produced VSV-G pseudotyped 
eGFP or Crimson-expressing chimeric HIV-2 MACA from selected donors along with a control sequence har-
boring MACA of HIV-2ROD. Efficient proteolytic cleavage of p57Gag was assessed on viral pellets by CA immu-
noblotting using an anti-HIV-2 serum (Fig. S2A) and virion infectivity was tested in a Mus dunni cell line, which 
do not have TRIM5alpha mediated restriction (Fig. S2B). The chimera #13 from a LTNP donor that includes a 
“GPT” motif had a low titer and was therefore not used in further experiments. Interestingly, all chimeras derived 
from the HIV-2 patients that have high viral load led to higher titers when compared to chimeras derived from 
individuals with low viral load (Fig. S2B).
Hu-TRIM5alpha does not efficiently restrict any of the HIV-2 primary CA isolates. SNP in genes 
involved in innate immunity, such as TRIM5alpha, may contribute to the difference in human susceptibility to 
HIV-1 infection and subsequent disease progression39,41,58. Since HIV-2 is more susceptible to TRIM5alpha than 
HIV-1, we wondered whether a correlation could be established between TRIM5 polymorphisms and suscepti-
bility to HIV-2 infection and disease progression in our patients. We therefore amplified and sequenced the exon 
8 of TRIM5alpha, corresponding to the PRY/SPRY domain that is required for capsid restriction59,60 from the 
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genomic DNA of the 18 donors. We found that one patient (#H1) had a heterozygous SNP with a substitution of 
a proline (P) for leucine (L) in the V4 region at position 479. We tested whether this SNP introduced a change in 
the susceptibility of CA from HIV-2 primary isolates, as compared to the reference hu-TRIM5alpha sequence. 
Dunni cells stably expressing WT hu-TRIM5alpha or the P479L allele were challenged with single-round VSV-G 
pseudotyped eGFP virions. Stable expression of hu-TRIM5alpha in these cells was verified by western blot anal-
ysis against its HA-epitope tag (Fig. S2C). As shown in Fig. 1A and B, the overall restriction profiles of WT and 
P479L hu-TRIM5alpha to all the HIV-2 CA were similar, and no specific susceptibility to TRIM5alpha WT or 
variant was observed for #H1 CA. This indicates that this mutation does not seem to play a role in the patient 
disease progression. This is in agreement with the fact that a P479L mutation found in one HIV-1 cohort study 
was not linked to infection or AIDS progression41. As observed by others45, CA from HIV-2 primary isolates 
have a greater susceptibility to hu-TRIM5alpha than to HIV-1. This enhanced HIV-2 susceptibility is present 
regardless of the disease status or the motifs in the capsid sequences (Table 1). Indeed, CA sequences as present in 
RP or LTNP patients were mildly restricted by hu-TRIM5alpha (ratio 0.7 to 0.8) while #15 CA (LTNP and motif 
“PPA”) and #10 CA (RP and motif “VPP”) were totally insensitive (Fig. 1A and B). However, the infectivity of the 
positive control CA (N-MLV) was highly reduced (ratio 0.01, p < 0.001) by WT hu-TRIM5alpha, but remained 
unaffected by P479L hu-TRIM5alpha to the same extent as B-MLV or SIVmac controls, which are resistant to 
restriction (Fig. 1A and B). Notably, the restriction activity against HIV-1-G89V, a mutant that lacks the ability 
to bind CypA (ratio 0.2, p < 0.001), which has already been observed by us and others43,57,61, was partially lifted 
(ratio 0.6) by the TRIM5alpha P479L mutation (Fig. 1A and B). This finding argues in favor of a direct interaction 
between CA and TRIM5alpha.
Inhibition of CypA binding by addition of CsA results in the restriction of virions harboring CA 
derived from HIV-2 primary isolates. CypA has been shown to bind HIV-1 CA and play a key role during 
HIV-1 infection and replication processes62. This binding has been shown to influence HIV-1 CA susceptibility 
to restriction factors63. Several lentiviruses bind CypA with high affinity, unlike SIVmac. Since the interaction 
of HIV-2 CA with CypA is still under debate55,56, we tested whether the susceptibility of some CA from HIV-2 
primary isolates to hu-TRIM5alpha were linked to CypA binding. For this purpose, we monitored single-round 
infectivity of virions that harbor different HIV-2 CA in the presence of cyclosporin A (CsA), a competitive inhib-
itor to CypA binding. As expected, addition of CsA had no effect on N and B-tropic MLV, as well as on SIVmac 
infections. HIV-1 infection was reduced twofold, in agreement with several studies that showed an interaction 
between HIV-1 CA and CypA (Fig. 1C). Infectivity of the HIV-1 G89V mutant that is unable to bind CypA, 
remained reduced as previously observed. Interestingly, all HIV-2 chimeras (including HIV-2ROD,) were more 
sensitive to hu-TRIM5alpha in the presence of CsA, although the restriction levels vary with the different primary 
isolate CA (Fig. 1C). Interestingly, CsA effect appeared to be dependent on stable expression of TRIM5alpha, as 
no effect was observed in dunni control cells (Fig. 1D) as compared to Fig. 1C. Altogether, these results unveiled 
a CypA dependence for HIV-2 CA mediated infection, similar to that of HIV-1.
Susceptibility of HIV-2 CA from primary isolates to TRIMCyp. Given that we have observed that 
all CA derived from HIV-2 primary isolates, as well as HIV-2ROD CA, were sensitive to the presence of CsA, we 
investigated whether HIV-2 CA from viremic or aviremic patients differed in their ability to bind to CypA. To 
this goal, we took advantage of TRIMCyp fusion proteins that are naturally present in several species of mon-
keys. Owl-TRIMCypA was described in owl monkeys64,65, while mafa-TRIMCypA and mamu-TRIMCypA 
proteins were found in different macaque species66,67. Mamu-TRIMCypA has been shown to block HIV-2 infec-
tion while owl-TRIMCypA and mafa-TRIMCypA proteins block HIV-1 infection67. We thus tested the infec-
tivity of different chimeric HIV-2 Gag in dunni cells stably expressing mamu-TRIMCypA, mafa-TRIMCypA 
or owl-TRIMCypA proteins. TRIMCypA expressions were confirmed by western blot using an anti-HA mAb 
(Fig. S2C). Consistent with a previous report67, we also observed that HIV-2ROD was strongly restricted by 
mamu-TRIMCypA while SIVmac, N and B-MLV, HIV-1 and the G89V mutant were not (Fig. 2A). Strikingly, 
Subject Viral load1 CDC stage2 HIV-2 Group
CA amino acid position3
119 159 178
HIV-2ROD prototype A P P P
 #13 < 99 A B G P T
 #14 < 99 A A P S P
 #15 < 99 A B P P A
 #18 < 99 A B A P A
 #10 862 C B V P P
 #H1 598 C A A P P
 #H4 5398 C A Q S P
 #H5 500 C A A S P
 #H8 2059 C B A P P
Table 1.  Clinical and virological parameters of HIV-2 infected patients analyzed in this study. 1Viral load 
on sampling date, copies/ml. 2According to CDC classification system for HIV infection. 3According to the 
HIV-2 ROD numbering (see Supplemental Fig. 1).
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all CA found in HIV-2 primary isolates were restricted as efficiently as HIV-2ROD CA (Fig. 2A). This is consistent 
with the fact that all the sequences of the CypA binding loop of the tested HIV-2 CA were closely related to each 
other with the deletion of an alanine residue at position 88, which is present in HIV-1 CA56. CypA-dependent 
susceptibility was confirmed by restoration of infectivity in the presence of CsA (Fig. 2D). As reported by others68, 
expression of mafa-TRIMCypA severely restricted HIV-1 infection while the HIV-1 G89V mutant and HIV-
2ROD escaped restriction (Fig. 2B). All HIV-2 CA from primary isolates that we tested were also insensitive to 
mafa-TRIMCypA with no effect from CsA, which lifted HIV-1 infectivity as expected (Fig. 2E). Surprisingly, 
although owl-TRIMCypA exhibited a restriction profile similar to that of mafa-TRIMCypA, we documented sig-
nificant differences in the levels of susceptibility of HIV-2 primary isolate CA to owl-TRIMCypA (Fig. 2C). Thus, 
we could distinguish two groups of restricted phenotypes. A group of CA, including that of HIV-2ROD, which were 
partially restricted (ranging from 2.5 to 3.3 fold). This group included isolates from both LTNP (#14,#15 and #18) 
and RP individuals (#H1,#H5 and #H8). A second group of CA that were robustly restricted (from 10 to 15 fold), 
that included isolates #10 and #H4, both derived from RP individuals (Fig. 2C). These distinctive levels of restric-
tion were also CypA dependent as all were abrogated upon CsA treatment (Fig. 2F). Intriguingly, despite their 
identical CypA binding loop sequences, CA #H4 and #H5 were distinctly sensitive to owl-TRIMCypA restriction, 
which unveiled the role of other determinants in CA that modulate CypA-dependent restriction. Nevertheless, 
this difference did not seem to explain progression to AIDS.
Figure 1. Mild restriction of HIV-2 infection by hu-TRIM5alpha proteins is increased by CsA treatment. 
Control dunni cells or dunni cells stably expressing TRIM5alpha WT- (A) or hu-TRIM5P479L (B) proteins 
were infected by VSV-G pseudotyped eGFP-expressing virions harboring either wt MLV-N, MLV-B, SIVmac, 
HIV-1 or HIV-2ROD CA, or the HIV-1G89V CA mutant, as controls; or the different chimeric SIVmac/HIV-2 
CAs. HIV-2 chimeric viruses from non progressor patients are shown in blue and those from progressor 
patients in red. (C) Restriction activity in dunni cells expressing WT hu-TRIM5alpha in the presence of 
Cyclosporin A (CsA). (D) Restriction activity in control dunni cells in the presence of CsA. Infected cells were 
counted by flow cytometry. Percentages of infected TRIM5alpha-negative control cells obtained with CA from 
LTNP or RP ranged between 14–30% and 50–82%, respectively. Fold changes in infectivity were calculated as 
the ratio of percentage of eGFP-positive TRIM5alpha-positive cells to that of eGFP-positive infected control 
dunni cells (A and B), the ratio between eGFP-positive TRIM5alpha-positive cells in the presence of CsA to 
the eGFP-positive infected control dunni cells (C), and the ratio between eGFP-positive control dunni cells 
in the presence of CsA to that of eGFP-positive control dunni cells without CsA. (D) Results are from at least 
three independent experiments. One-way ANOVA with Tukey’s multiple comparisons test was used to assess 
significance. SEM and P-values are indicated (*P < 0.05; **P < 0.01 ***P < 0.001; ****P < 0.0001).
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HIV-2 infection dependence to CypA. Since the results presented above unveiled a potential role of CypA 
in HIV-2 infection, we tested whether depletion of CypA in human cells influenced HIV-2 early-steps of infec-
tion. For this purpose, we compared infection levels of all HIV-2 chimeras in parental or PPIA−/− Jurkat cells. In 
the latter cells, both alleles of the CypA-encoding PPIA have been inactivated69. While infectivity of the HIV-1 
G89V mutant was sustained (ratio 0.9), all HIV-2 CA tested were significantly impacted by the lack of CypA, 
although to a lower extent than WT HIV-1 CA (Fig. 3). Of note, infection by chimera #15 that was isolated from 
an LTNP donor, was as affected that HIV-1 by the lack of CypA. These results strengthen our observation that 
there is a crucial and general role for CypA binding in HIV-2 infections of human cells.
CA from HIV-2 primary isolates is the determinants for infectivity dependency on Nup358 and 
Nup153. In contrast to other retroviruses, lentiviruses have the ability to productively infect non-dividing 
Figure 2. Owl-TRIMCypA and mamu-TRIMCypA restrict HIV-2 infection. Control dunni cells or dunni 
cells stably expressing either mamu-TRIMCypA (A), mafa-TRIMCypA (B) or owl-TRIM5CypA (C) were 
infected by the VSV-G pseudotyped eGFP-expressing virions described in Fig. 1. Restriction activity in the 
presence of CsA (D to F) was expressed as fold change in infectivity and calculated as in Fig. 1. Results are from 
at least three independent experiments. One-way ANOVA with Tukey’s multiple comparisons test was used to 
assess significance. SEM and P-values are indicated (****P < 0.0001).
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cells, and it has been shown that this ability is conferred by the CA determinants70,71. In a previous study we found 
that, like HIV-1, HIV-2ROD prototypic infection was decreased upon depletion of Nup358 or Nup153, suggesting 
a common pathway to enter the nucleus57. Here, we examined whether the CA from primary HIV-2 isolates had 
similar dependence to these nucleoporins. We transduced Jurkat cells with a lentiviral vector expressing control 
shRNA (mock) or a shRNA targeting either Nup358 or Nup153. Specific depletion of the proteins was verified by 
immunoblotting of whole cells extracts from stable Nup358 or Nup153-depleted Jurkat cells (Fig. 4A and B). As 
expected, upon knockdown of Nup358, MLV-B infection was unaffected while HIV-1 and HIV-2ROD infections 
were significantly inhibited when compared to control Jurkat cells (Fig. 4C). Infectivity of CA determinants from 
HIV-2 primary isolates from either LTNP patients or RP donors were also inhibited (ratio 0.45 to 0.6) (Fig. 4C). 
However, the dependence of CA from LTNP HIV-2 patient #18 to Nup358 was marginal (ratio 0.85) (Fig. 4C).
Nup358 has a C-terminal domain that is homologous to CypA, which has been shown to bind HIV-1 CA72,73. 
We previously generated a pLXSN retroviral vector encoding a synthetic TRIMCypNup358 protein that com-
prises the RBCC domain of owl-TRIMCypA fused to the Nup358CypA domain. We derived dunni cells that 
stably expressed the chimeric TRIMCypNup358 protein, and confirmed expression of the fusion protein by west-
ern blot with an anti-HA antibody (Fig. S2C). Strikingly, in contrast to SIVmac and HIV-1 G89V, HIV-1 and 
HIV-2 prototypes and all the CA from HIV-2 primary isolates were strongly restricted by TRIMCypNup358, 
thus demonstrating a direct interaction of CA with the Nup358 CypA-like domain (Fig. 4D). Although the 
CypA-binding loop of HIV-2 CA is quite different from that of HIV-1, our present finding is in accord with the 
fact that the Nup358 CypA-like domain is involved in the interaction of the latter with HIV-1 CA74,75. Of interest, 
this contrasted with our previous study wherein we found no correlation between sensitivity of circulating SIV 
isolates to Nup358 depletion and restriction by TRIMCypNup35857.
While the MLV-B control is not affected by stable Nup153 depletion in Jurkat cells, this depletion significantly 
and specifically altered infectivity of HIV-1 and HIV-2ROD as well as that of all primary HIV-2 isolates (ratio 0.25 
to 0.65) (Fig. 4C).
Discussion
HIV-1 and HIV-2, which arose from distinct SIV zoonotic transmissions, present several differences in terms of 
originating species, geographical distribution, replication, transmission, and progression to AIDS12. Furthermore, 
while HIV-1 patients that meet the criteria of LTNP are rare, most HIV-2 infected patients exhibit LTNP virological 
and clinical profiles. Nevertheless, as some HIV-2 infected individuals will develop AIDS, few data are available on 
interactions of CA with host factors that would characterize this stage. In this study, we evaluated the ability of HIV-2 
primary isolate capsids to interact with host cellular factors known to negatively or positively modulate HIV-1 infec-
tion. For this purpose, we derived and compared CA from individuals with high viral load that were rapidly pro-
gressing to AIDS versus those from HIV-2 infected patients with undetectable viral load and considered as LTNPs.
As previously reported by others, we found that HIV-2 CA from primary isolates were more susceptible to 
hu-TRIM5alpha than HIV-1 CA. The role of proline residues at CA positions 119, 159 and 178 has been associ-
ated with highest hu-TRIM5alpha susceptibility for HIV-2ROD CA45,47,48. In contrast, we did not find any obvious 
Figure 3. Optimal infection by HIV-2 isolates requires CypA. Jurkat cells or Jurkat PPIA−/− cells were 
infected by VSV-G pseudotyped eGFP-expressing virions harboring either HIV-1 wt, HIV-1 G89V mutant, or 
HIV-2ROD CA as controls, or the chimeric SIVmac/HIV-1 CA (HIV-1) or SIVmac/HIV-2 CA. HIV-2 chimeric 
viruses from non progressor patients are shown in blue and those from progressor patients in red. Infection 
levels were determined as in Fig. 1, as the ratio of percentage of PPIA− /− Jurkat cells that were GFP-positive to 
GFP-positive control Jurkat cells. Results are from at least two independent experiments. Unpaired two-tailed 
Student’s t-test was used to assess significance. SEM and P-values are indicated (**P < 0.01; ***P < 0.001).
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correlation between the “PPP” pattern found in the primary isolate CA and viral load, progression to disease, or 
susceptibility to hu-TRIM5alpha, as tested in vitro. Furthermore, although all CA motifs found in rapid progressors 
harbored a P178 these CA were marginally or not detectably restricted by hu-TRIM5alpha. Therefore, our observa-
tions argued in favor of a key role for other CA residues with regard to susceptibility of HIV-2 to hu-TRIM5alpha.
Cohort studies have suggested that some hu-TRIM5alpha SNPs are associated with a protective effect against 
HIV-1 infection39,41. However, to our knowledge, no population study has reported a correlation between 
hu-TRIM5alpha polymorphism and HIV-2 susceptibility in vivo. Although we found that the TRIM5alpha P479L 
SNP, located in the PRY/SPRY domain of a RP patient, did not change the restriction pattern towards HIV-2 
CA, it would remain of interest to evaluate larger cohorts of HIV-2 patients for the possible contribution of 
hu-TRIM5alpha polymorphisms to HIV-2 replication.
It has been reported that HIV-2 does not require host CypA for efficient replication in human cells54. 
Even if a weak binding between HIV-2 CA and CypA has been detected in a previous report56, the interac-
tion of the HIV-2 CA with CypA remains debated. We found that addition of CsA in mouse dunni cells that 
over-express hu-TRIM5alpha enhanced the restriction activity against all tested CA from HIV-2 primary 
isolates. CsA is known to bind CypA and to inhibit its interaction with other proteins. Since CsA enhanced 
hu-TRIM5alpha-mediated restriction of all CA from HIV-2 primary isolates, this indicated that these isolates 
required CypA for optimal replication. As the amino acid sequences of mouse and human CypA are 98% identi-
cal, it is unlikely that CypA differences between species could play a role in this phenotype.
In this context, we evaluated whether CA HIV-2 primary isolates differed in their potential binding to 
hu-CypA and subsequent infectivity. The efficient restriction observed with the natural owl-TRIMCypA on all 
HIV-2 primary isolate CA strongly suggests that all CA from primary isolates can interact with CypA. We found 
that these interactions resulted in a drop of the infectivity mediated by the HIV-2 CA, even in the case of two 
HIV-2 CA that were derived from rapid progressors, reaching the same levels of restriction as that seen with 
Figure 4. Modulation of Nup358 and Nup153 expression, impact on infection by HIV-2 isolates and CA 
binding. Levels of expression of Nup358 (A), Nup153 (B), or lamin-B in control Jurkat cells that stably express 
shRNA against either a non-vertebrate gene (shMock), Nup358 or Nup153. (C) Cells in A and B were challenged 
with MLV-N or HIV-1wt CA as controls, and recombinant viruses carrying multiple HIV-1 or HIV-2 CA 
sequences. Infection levels were determined as in Fig. 1, as the ratio of the percentage of Crimson+ and Nup358 
KO (black bars) or Nup153 KO (grey bars) Jurkat cells, to Crimson + shMock control Jurkat cells. The names 
of the HIV-2 chimeric viruses from non progressor patients are shown in blue and those from progressor 
patients in red. Unpaired two-tailed Student’s t-test was used to assess significance. SEM and P-values are 
indicated (*P < 0.05; **P < 0.01). (D) Control dunni cells and dunni cells expressing TRIMNup358Cyp were 
infected with the virions described above, MLV virions excluded. Restriction activity in dunni cells that were 
GFP-TRIMCypNup358 positive was calculated as described above in comparison with GFP-positive control 
dunni cells. Chimeric viruses from non progressor or progressor patients are as above. Results are from at least 
three independent experiments. Unpaired two-tailed Student’s t-test was used to assess significance. SEM and 
P-values are indicated (***P < 0.001).
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HIV-1 CA. This was confirmed by the reduced infectivity of HIV-2ROD prototype and all the HIV-2 primary iso-
late CA we tested in Jurkat PPIA−/− cells when compared to Jurkat cells. Nevertheless, no difference in CypA-CA 
interactions could be established between CA from rapid progressors versus LTNPs. Therefore, in contradiction 
to some previous studies, our results underline the fact that HIV-2, like HIV-1, is dependent on CypA for optimal 
infection in human cells. Assessing whether more subtle differences in the binding affinity of HIV-2 CA to CypA 
play a role in disease progression will require more highly sensitive measurements.
Indeed, it was recently reported that the affinity of HIV CA for CypA affects sensing of viral DNA mediated 
by cGas in monocyte-derived dendritic cells34 and may contribute to the differential pathogenesis of HIV-2 in 
LTNPs versus RPs.
CypA, Nup153 and Nup358 interact with CA and have been described to be part of a pathway that mediates 
HIV-1 nuclear import73,75–77. In a previous study, we have shown that HIV-2ROD exploits the same pathway, while 
circulating SIV isolates can use alternative pathways to enter the nucleus57. Here, we tested the status of HIV-2 
primary isolates with regard to Nup153 or Nup358 interaction, and found that all CA from HIV-2 primary iso-
lates were sensitive to the absence of Nup358. Although infectivity of HIV-2 CA derived from #18 LTNP seemed 
less affected by Nup358 depletion, all HIV-2 infections were strongly restricted by the artificial TRIMCypNup358 
fusion protein. This demonstrated the general ability of HIV-2 primary isolate CA to directly bind to Nup358 
Cyp-like domain, as previously described for HIV-1 and for HIV-2 prototypes57,73. Binding of HIV-1 CA to the 
Cyp-like domain of Nup358 depends on residue P9075. Although the CypA-binding loop of HIV-2 CA is shorter 
than that of HIV-1 CA, the corresponding GP motif is maintained in all HIV-2 primary isolate CA. It is therefore 
tempting to speculate that HIV-2 CA may be isomerized since Nup358 is required for its infection. However, 
despite the fact that FIV CA binds Nup358, the CA does not use Nup358 as co-factor and is not propyl isomerized 
by the Cyp-like domain of Nup35875.
We found that all HIV-2 infections were also decreased upon Nup153 depletion. Others have previously 
shown that binding of HIV-2ROD CA and HIV-1 CA to Nup153 is required for optimal infection, especially in 
association to four residues, N56, Q66, R69, N73 in HIV-2ROD CA77. Accordingly, all four residues were con-
served in HIV-2 primary isolates tested here. We further observed that this dependence of HIV-2 primary iso-
lates and HIV-1 on the same cellular co-factors also extended to TNPO3 (data not shown); of note, TNPO3 is 
a karyopherin known to transport SR family proteins, which has been also implicated in the Nup358/Nup153 
pathway78,79. As the decrease of infectivity of HIV-1 upon TNPO3 depletion has been shown to be dependent on 
cleavage and polyadenylation specific factor 6 (CPSF6)80, we hypothesized that the proposed model for HIV-1 
nuclear entry could also be applied to HIV-2 nuclear entry74,81. Interestingly, both SIVcpz and SIVsm adaptation 
to human cells seems to exploit the same co-factors and pathway for nuclear import. Although these cellular 
factors appeared to be recruited by the two epidemic groups A and B, it may not be the case for other groups that 
may have had fewer, if not a single, transmission events.
We found that sensitivity to the cellular host factors we tested and HIV-2 disease progression remained dis-
sociated. However, here we showed that CypA dependence is a common trait of all HIV-2 CA from primary 
isolates. Nevertheless, while requiring CypA, these isolates may still differ in their requirements for other factors 
that interact with HIV-1 CA. Such potentially distinctive factors include the recently identified protein SUN2 that 
seems essential for HIV-1 infection of CD4+ T cells82,83, or MX2, which has been reported to inhibit HIV-1 infec-
tion28,84. Assessing interaction of HIV-2 primary isolate CA with the latter would be of particular interest since it 
is induced by IFN and since HIV-2 has been shown to be less resistant than HIV-1 to IFN response85.
Methods
PCR amplification and sequencing of the TRIM5alpha PRY/SPRY region. Genomic DNA was 
extracted from PBMC from 18 patients from the French ANRS CO5 HIV-2 cohort using the QIAamp blood 
kit (Qiagen), according to the manufacturer’s instructions. Written informed consents were obtained for all 
patients at the time of inclusion in the cohort. All experiments were performed in accordance with relevant 
guidelines and regulations. This study was approved by the ethics committee (CPP Ile-de-France IX). For anal-
ysis of variations in the TRIM5 exon8, DNA samples were amplified by PCR using the Expand High Fidelity 
PCR System (Roche Diagnostics) with the specific primers (5′ -GGTTCCTCCCAGTTTTCTCTCAAG-3′ ) and 
(5′ -GAAGGGGCTGAGTGTGTAAGAAGG-3′ ). The PCR products were purified using the PCR clean-up Gel 
Extraction kit (Macherey Nagel) according to manufacturer’s protocol and used for direct Sanger sequencing. 
DNA sequencing chromatograms were examined visually to detect heterozygous SNPs at each position using 
Geneious Pro software and amino acid sequences were aligned using Clustal W.
Generation of cells stably expressing TRIM5 variants. The full-length cDNA from human 
TRIM5alpha was obtained from RT-PCR amplification of HeLa cells RNA. The TRIM5alpha P479L was obtained 
by recombinant PCR by exchanging the human TRIM5alpha exon 8 with the corresponding mutated allele from 
patient #H1. The full-length owl-TRIMcypA cDNA was PCR amplified from plasmid pMIG-TRIMCyp obtained 
from the NIH AIDS reagents program65. Mafa-TRIMCypA and mamu-TRIMCypA were kind gifts of Dr. Greg 
Towers68,86. The TRIM-CypNup358 was obtained by recombinant PCR as previously described57. All PCR prod-
ucts were cloned into a retroviral vector containing two C-terminus hemagglutinin (HA) tags derived from 
pLXSN (Clontech). HEK-293T cells were then independently co-transfected with the pLXSN-based retroviral 
vectors encoding the various HA-tagged TRIM5 variants along with plasmids expressing MLV Gag-Pol and the 
vesicular stomatitis virus (VSV) G envelope glycoprotein (pCSIG)87. Forty-eight hours after transfection, the 
retroviral supernatants were harvested and used to transduce dunni cells grown in the presence of G418 at 2 mg/
ml (Invivogen) to select stable expression of TRIM5.
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Chimeric gag-pol SIVmac expression plasmids. The HIV-2 gag matrix-capsid fragments (MACA) 
were PCR amplified from DNA extracted from pelleted PBMCs from 18 infected patients of the French ANRS 
CO5 HIV-2 cohort. The MACA PCR products were first subcloned into a pUC19 vector containing a fragment 
of a gag-pol SIVmac251 expression plasmid (pAd-SIV4)88 as previously described57. The most represented CA 
sequence obtained from the patient was then introduced into the pAd-SIV4 vector to obtain chimeric gag-pol 
SIVmac expression plasmids. The HIV-1 and HIV-1G89V gag fragments were PCR amplified from the p8.91 and 
p8.91G89V, gag-pol expression plasmids, respectively89,90.
Cell culture. HEK-293T and Mus Dunni (dunni) cells91 were cultivated in Dulbecco modified Eagle medium 
supplemented with 10% fetal bovine serum (FBS), non-essential amino acids and penicillin 100 U/ml and strep-
tomycin 0.1 mg/ml at 37 °C and 5% CO2-air atmosphere. Jurkat cells were grown in RPMI containing 10% FBS. 
Jurkat T-Cells CypA− /− were obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, 
from Drs. D. Braaten and J. Luban69.
Infection with VSV-G pseudotyped viruses expressing green fluorescent protein (GFP). HIV-1, SIVmac 
and chimeric HIV-2 vectors carrying the green fluorescent protein (GFP)-reporter gene were generated by 
co-transfecting HEK-293T cells with three expression vectors; (i) a Gag-Pol expression vector (p8.91 N∆ SB 
for HIV and pAd-SIV4 for SIVmac and chimeric SIV) (ii) the VSV-G envelope glycoprotein expression vector 
(pCSI-G), which allows efficient virion fusion into the mammalian cell lines, and (iii) a vector providing a pack-
ageable GFP-containing retroviral RNA genomes: pSIN CSGW92 for HIV genomes and GAE-SFFV-GFP-WPRE 
for SIV genomes88. Virus-containing culture supernatant was harvested 48h after transfection and filtered 
through a 0.45 μ m-pore-size filter before immediate storage at − 80 °C until use.
Viral stock infectious titers were determined via GFP expression by flow cytometry 48h after viral challenge of 
non-restricting dunni cells. All infections were performed in 96-well plates, wherein 2 × 104 cells were incubated with 
two-fold serial dilutions of the challenging virus. Polybrene was used in all transductions at a concentration of 4μ g/ml. 
When required, Cyclosporin-A (Sigma-Aldrich) was added at a concentration of 5μ g/ml. Cells were then incubated 
at 37 °C/5%CO2. GFP-positive cells were enumerated 48h later on a FACSCalibur flow cytometer (Becton Dickinson) 
after collection of at least 10,000 events. Data analyses were performed using FlowJo 7.6.1 software (Tree Star).
shRNA transduction and infection with VSV-G pseudotyped viruses expressing E2-Crimson 
fluorescent protein. The sequences of shRNA pLK0.1-GFP plasmid for Nup358 were as described in69 
with a modification to the hairpin loop by adding the nucleotides of the human miR-30 loop. The sequence 
of shRNA pLK0.1-GFP plasmid Nup153 was from Sigma-Aldrich (SHCLNG-NM_005124). Virions were pro-
duced in a similar way as HIV-1 VSV-G pseudotyped viruses. After transduction, Jurkat cells were sorted twice 
for GFP-positive populations using a BD FACSAria cell sorter (Becton Dickinson). GFP Jurkat cells were then 
infected with VSV-G-pseudotyped Crimson reporter viruses.
Western blotting. Dunni cells stably expressing HA-tagged TRIM5 variants were lysed in 100 mM NaCl, 
50 mM Tris (pH 7.5) and 1% Triton X-100 containing protease inhibitors (Sigma-Aldrich). Proteins were sepa-
rated on a 10% acrylamide gel, transferred onto PVDF membrane and probed with a rat anti-HA antibody (3F10, 
Roche Applied Science). A peroxidase-conjugated goat anti-rat (SouthernBiotech) was used as secondary anti-
body. Loading was controlled by probing with a β -actin antibody. For CA detection, conditioned cell-free super-
natants of transfected HEK-293T cells were pelleted through a 20% sucrose layer in TEN buffer (10 mM Tris.
HCl pH7.5; 100 mM NaCl; 1 mM EDTA) at 25000 rpm for 2h30 at 4 °C in a SW 40 Ti rotor. Pelleted viruses were 
probed for CA content using sera from HIV-2 infected patients and anti-human-IgG-HRP IgG (Sigma-Aldrich) 
as primary and secondary antibodies, respectively.
Protein depletion by shRNA in Jurkat cells was monitored by immunoblotting using a rabbit polyclonal 
antibody against Nup358/RanBP2 (ab64276, Abcam) and mouse Nup153 antibodies (ab24700, Abcam) with a 
peroxidase-conjugated goat anti-rabbit and anti-mouse as secondary antibodies, respectively (Sigma-Aldrich). 
Lamin-B was used as a loading control.
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SUPPLEMENTARY	  INFORMATION	  
Cyclophilins	  and	  nucleoporins	  are	  required	  for	  infection	  mediated	  by	  capsids	  from	  
circulating	  HIV-­‐2	  primary	  isolates	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Figure	  S1	  
Comparison	  of	  CA	  sequences	  found	  in	  patients	  with	  the	  HIV-­‐2ROD	  prototype.	  Sequence	  
alignment	  of	  matrix	  and	  capsid	  amino	  acid	  residues	  of	  HIV-­‐2ROD	  prototype	  with	  those	  of	  HIV-­‐
2	  primary	  isolates	  found	  in	  aviremic	  patients,	  in	  blue	  (#13,	  #14,	  #15	  and	  #18	  ),	  or	  viremic	  
patients,	  in	  red	  (#10,	  #H1,	  #H4,	  #H5	  and	  #H8).	  We	  cloned	  and	  sequenced	  around	  8-­‐10	  clones	  
for	  each	  patient	  sample	  and	  chose	  the	  most	  frequent	  sequence.	  Dots	  represent	  fully	  
conserved	  residues	  and	  deletions	  are	  indicated	  with	  dashes.	  Numbering	  of	  MA	  and	  CA	  
residues	  is	  indicated	  following	  HIV-­‐2	  ROD	  sequence.	  Also	  indicated	  are	  the	  beginning	  of	  CA	  
and	  the	  CypA-­‐binding	  loop.	  Proline	  residues	  corresponding	  to	  HIV-­‐2ROD	  position	  119,	  159	  and	  
178	  are	  in	  bold	  and	  marked	  with	  a	  star.	  
	  
Figure	  S2	  
Monitoring	  of	  protein	  expression	  and	  infection.	  (A)	  Western	  blot	  analysis	  of	  the	  different	  
HIV-­‐2	  CA	  chimera	  proteins.	  Viral	  supernatants	  were	  harvested	  48h	  after	  transfection	  of	  HEK-­‐
293T	  cells	  with	  the	  wild-­‐type	  or	  chimeric	  SIVmac	  gag-­‐pol	  expression	  vectors,	  a	  SIVmac-­‐based	  
GFP	  retroviral	  vector	  and	  the	  vesicular	  stomatitis	  virus	  G	  expression	  vector.	  Virions	  were	  
pelleted	  by	  ultracentrifugation	  through	  a	  20%	  sucrose	  cushion	  and	  CA	  proteins	  were	  
detected	  using	  serums	  from	  HIV-­‐2	  infected	  patients.	  B)	  Infection	  efficiency	  of	  serial	  dilutions	  
for	  each	  HIV-­‐2	  chimera	  in	  dunni	  cells	  is	  measured	  as	  percent	  of	  GFP-­‐positive	  cells,	  48h	  after	  
infection.	  Absolute	  titers	  for	  all	  viruses	  were	  as	  follows	  :	  (%	  GFP	  :	  SIVmac	  =	  75.2;	  ROD=65.3;	  
#14=15.23;	  #15=28.4;	  #18=28.81;	  #10=65.2;	  #H1=80.5;	  #H4=46.8;	  H5=78.2;	  #H8=72).	  C)	  
Stable	  expression	  of	  TRIM5alpha	  and	  TRIM5cyp	  fusion	  proteins	  in	  dunni	  cell	  lines.	  Cell	  
extracts	  were	  obtained	  from	  control	  dunni	  cells	  and	  dunni	  cells	  transduced	  with	  vectors	  
encoding	  HA-­‐tagged	  TRIM5alpha	  from	  human	  (WT	  or	  mutant	  1/1	  and	  1/6P479L	  -­‐	  hu-­‐
TRIM5alpha	  from	  2	  independent	  populations	  of	  dunni	  cells	  that	  stably	  express	  hu-­‐
TRIM5alpha	  P479L);	  TRIM5CypA	  proteins	  from	  owl	  monkey	  (owl-­‐TRIMCypA),	  Macaca	  
mulatta	  (mamu-­‐TRIMcypA)	  and	  Macaca	  fascicularis	  (mafa-­‐TRIMcypA).	  TRIMCypNup358	  
corresponds	  to	  a	  synthetic	  TRIMCyp	  protein	  obtained	  by	  fusing	  TRIM5	  RBCC	  of	  TRIMCypA-­‐
owl	  with	  the	  human	  CypA	  protein.	  Immunoblotting	  was	  performed	  with	  monoclonal	  
antibodies	  directed	  against	  HA.	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  binding	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 #13 ..........I........................E.......V.....D...D..Q...S................... 
 #14 ...D.R.....................................V.........D..A....................... 
 #15 .I.D...............................E.................D..Q...V..........D........ 
 #18 ...D...............................E.................D..Q...V..........D........ 
 #10 ...................................E.................D..Q..............D........ 
 #H1 ........................................................T....................... 
 #H4 ...D.................................................D..A..............D........ 
 #H5 ...D.................................................D..A..............D........ 
 #H8 .I.................................E.................D..Q....................... 
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